Business Wire

Chappellet Becomes the Only American Winery to Be Named a Relais & Châteaux Preferred Partner

7.2.2023 17:00:00 EET | Business Wire | Press release

Share

Napa Valley’s acclaimed Chappellet winery ( www.chappellet.com ) is excited to announce that it has been invited to become a Relais & Châteaux Preferred Partner. With this honor, Chappellet becomes the first American winery to be invited to become a Preferred Partner and joins an exclusive list of some of the world’s top wineries to be named a Relais & Châteaux Partner. Established in 1954, Relais & Châteaux is an association of more than 580 hotels and restaurants around the world operated by independent innkeepers, chefs, and owners who share a passion for excellence and a desire for authenticity in their relationships with their clientele. Preferred Partners are selected based on their shared values with Relais & Châteaux and their ability to provide unique and unforgettable experiences in their signature areas of expertise. “As a multigeneration, family-owned-and-operated winery that shares Relais & Châteaux's values and passion for excellence, we are thrilled to build on our longstanding relationship with Relais & Châteaux as a Preferred Partner,” said Cyril Chappellet, the second-generation president and chairman of Chappellet.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005010/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

View of Chappellet’s renowned estate vineyard on Pritchard Hill. (Photo: Business Wire)

Founded in 1967 by legendary vintners Donn and Molly Chappellet, Chappellet was the second post-Prohibition winery established in the Napa Valley. Inspired by the notion that “Bacchus loves the hills,” the Chappellet family settled on Pritchard Hill in the eastern mountains of Napa Valley, where they became some of the earliest pioneers of high-elevation vineyard planting. Though grapes grown above 1,000 feet represent only approximately 3% of total production in California, mountain-grown wines represent a significant portion of the most iconic and sought-after wines in America. Still independent and family-run today, Chappellet’s mountain-grown Cabernet Sauvignons from Pritchard Hill have earned global renown and are recognized as benchmarks for their region, having received multiple 100-point scores and glowing comparisons to the First Growths of Bordeaux from top wine critics.

“Since 1967, our family’s winery on Pritchard Hill has been dedicated to crafting world-class, mountain-grown Cabernet Sauvignon,” added Cyril Chappellet. “Like each Relais & Châteaux property, we strive for perfection in everything we do, from the meticulous way we organically farm our vineyard to the deep and enduring bonds we forge with our customers. Over the years, we have enjoyed remarkable relationships with many Relais & Châteaux owners and properties in North America. We look forward to building on these strong connections as we grow our presence around the globe.”

Chappellet has been partnering with a number of Relais & Châteaux properties in North America over the past decade, hosting curated weekends for their collectors at prestigious properties that include Triple Creek Ranch in Montana, The Wauwinet in Nantucket, Massachusetts, Planters Inn in Charleston, South Carolina and Auberge du Soleil in Napa Valley, California.

“I have had the pleasure of working with Chappellet at multiple Relais & Châteaux properties for the last 15 years,” said Molly Smith, the general manager of Triple Creek Ranch. “The history, familiarity, and elegance that the winery has carried through to the guests has elevated experiences and memories.”

As a Preferred Partner, Chappellet will be hosting additional special “Collectors’ Weekends” for both Relais & Châteaux members and Chappellet collectors at Relais & Châteaux properties throughout North America in 2023. The winery will also be developing new ways to engage with Relais & Châteaux members and its global association of restaurants and hotels, including vintner dinners, tasting events, wine education experiences, and the expansion of Chappellet’s “Collectors’ Weekends” into Europe and Asia.

In commenting on Chappellet’s new status as a Preferred Partner, David Fink, the proprietor of Relais & Châteaux property L'Auberge Carmel, said, “More than half a century ago, Donn Chappellet left his corporate life in Los Angeles to find one of the most idyllic places to raise a family and become a wine grower. Today, the Chappellet family carries Donn's vision forward and has created some of the most special wines made in California.”

About Chappellet
In 1967, on the advice of legendary winemaker André Tchelistcheff, the Chappellet family settled on the steep slopes of Pritchard Hill© and founded Chappellet, becoming just the second post-Prohibition winery in Napa Valley. As pioneers of high-elevation vineyard planting, Chappellet has earned acclaim for crafting benchmark wines with an emphasis on mountain-grown Cabernet Sauvignons, while establishing Pritchard Hill as one of the world’s great wine regions.

About Relais & Châteaux - A Movement with Meaning
Relais & Châteaux, established in 1954, is an association of 580 unique hotels and restaurants throughout the world, owned and operated by independent entrepreneurs – most often families – who are passionate about their craft and deeply committed to forging warm, lasting relationships with their guests. Relais & Châteaux members protect and promote the wealth and diversity of the world’s culinary and hospitality traditions, to ensure they continue to thrive. They are equally dedicated to preserving local heritage and the environment, as articulated in the association’s Vision presented to UNESCO in November 2014. For more information, visit www.relaischateaux.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Sonia Ginsburg
Sonia@jam-pr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye